PAREXEL International Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PAREXEL International Corporation - overview
Established
1982
Location
Durham, NC, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 1982, PAREXEL International Corporation (Parexel) operates as a clinical research organization (CRO) and biopharmaceutical services company. As of 2024, the firm is headed by its CEO Jamie Macdonald. In July 2021, EQT and Goldman Sachs Asset Management agreed to fully acquire PAREXEL International Corporation from Pamplona Capital Management for USD 8. 5 billion.
The company provides expertise-based clinical trial solutions including clinical research, consulting, outsourcing services, portfolio management and asset valuation, early development and innovation, integrated clinical development, and many others. The firm’s innovation areas include patient centricity, precision medicine, adaptive and flexible trials, real-world data trials, and innovation imperative. The organization's therapeutic areas include oncology, cardiovascular and metabolic, central nervous system (CNS), infectious disease, ophthalmology, respiratory, rheumatology and immunology, rare diseases, and regenerative medicine.
Current Investors
EQT, Goldman Sachs Asset Management, Wellco Capital
Primary Industry
Biotechnology
Sub Industries
Consulting Services, Outsourcing, Biopharmaceuticals, Pharmaceutical Research & Development, Literary Publishing
Website
www.parexel.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
PAREXEL International Corporation - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | PAREXEL International Corporation | - | ||||||||
| Spin-Off | Completed | Calyx | - | ||||||||
| Public to Private | Completed | PAREXEL International Corporation | - | ||||||||
| Trade Sale | Completed | Liquent, Inc. | - | ||||||||
| Trade Sale | Completed | Clinphone | - |
Displaying 1 - 5 of 8
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.